key: cord-0685027-1n79xuuz
authors: Balushi, Asma Al; AlShekaili, Jalila; Kindi, Mahmood Al; Ansari, Zainab; Al-Khabori, Murtadha; Khamis, Faryal; Ambusaidi, Zaiyana; Balushi, Afra Al; Huraizi, Aisha Al; Sulaimi, Sumaiya Al; Fahdi, Fatma Al; Balushi, Iman Al; Pandak, Nenad; Fletcher, Tom; Nasr, Iman
title: Immunological predictors of disease severity in patients with COVID-19
date: 2021-07-01
journal: Int J Infect Dis
DOI: 10.1016/j.ijid.2021.06.056
sha: 9ffd21c599cedb2aa6c57f3fe08c240412ed51ee
doc_id: 685027
cord_uid: 1n79xuuz

BACKGROUND: : Identifying immune cells involved in COVID-19 disease progression and predictors of poor outcomes is important to manage patients adequately. METHODS: : A prospective observational cohort study enrolled 53 mild non-hospitalized and 48 hospitalized confirmed COVID-19 patients to a tertiary hospital in Oman. RESULTS: : Hospitalized patients were older (58 years vs 36 years, p <0.001) and had more comorbid conditions like diabetes (65 % Vs 21% p<0.001). Hospitalized patients had significantly higher inflammatory markers (p<0.001); C-reactive protein (CRP) (114 vs 4 mg/L), Interleukin-6 (IL-6) (33 vs 3.71pg/ml), lactate dehydrogenase (LDH) (417 vs 214 U/L), ferritin (760 vs 196 ng/mL), fibrinogen (6 vs 3 g/L), D-dimer (1.0 vs 0.3 mcg/mL), disseminated intravascular coagulopathy (DIC) score (2 vs 0) and neutrophil/lymphocyte ratio (4 vs 1.1), (p<0.001). In multivariate regression analysis, statistically significant independent early predictors of ICU admission or death were higher levels of IL-6 (OR 1.03, p=0.03), frequency of large inflammatory monocytes (CD14+CD16+) (OR 1.117, p=0.010) and frequency of circulating naïve CD4+ T cells (CD27+CD28+CD45RA+CCR7+) (OR 0.476, p=0.03). CONCLUSION: : IL-6, frequency of large inflammatory monocytes, and circulating naïve CD4 T cells can be used as independent immunological predictors of poor outcomes in COVID-19 patients to prioritize critical care and resources.

 COVID-19 severity predictors help to prioritize resources and minimize mortality  Immunological markers can be used as predictors of poor prognosis  High IL-6 independently predicts poor outcomes in COVID-19 patients  High percentage of large inflammatory monocytes predicts worse COVID-19 outcomes  Lower circulating Naïve CD4+ T cells predicts poor prognosis in COVID-19 patients Abstract:

Background: Identifying immune cells involved in COVID-19 disease progression and predictors of poor outcomes is important to manage patients adequately.

Methods: A prospective observational cohort study enrolled 53 mild non-hospitalized and 48 hospitalized confirmed COVID-19 patients to a tertiary hospital in Oman.

Results: Hospitalized patients were older (58 years vs 36 years, p <0.001) and had more comorbid conditions like diabetes (65 % Vs 21% p<0.001). Hospitalized patients had significantly higher inflammatory markers (p<0.001); C-reactive protein (CRP) (114 vs 4 mg/L), Interleukin-6 (IL-6) (33 vs 3.71pg/ml), lactate dehydrogenase (LDH) (417 vs 214 U/L), ferritin (760 vs 196 ng/mL), fibrinogen (6 vs 3 g/L), D-dimer (1.0 vs 0.3 mcg/mL), disseminated intravascular coagulopathy (DIC) score (2 vs 0) and neutrophil/lymphocyte ratio (4 vs 1.1), (p<0.001). In multivariate regression analysis, statistically significant independent early predictors of ICU admission or death were higher levels of IL-6 (OR 1.03, p=0.03), frequency of large inflammatory monocytes (CD14+CD16+) (OR 1.117, p=0.010 ) and frequency of circulating naïve CD4+ T cells (CD27+CD28+CD45RA+CCR7+) (OR 0.476, p=0.03) .

Conclusion: IL-6, frequency of large inflammatory monocytes, and circulating naïve CD4 T cells can be used as independent immunological predictors of poor outcomes in COVID-19 patients to prioritize critical care and resources.

COVID-19, lymphocyte subsets, Inflammatory markers, Immunological predictors, mortality predictors Introduction:

novel coronavirus has been identified as the cause, named later as Severe Acute Respiratory Syndrome -2 (SARS-CoV-2) (Lai et al. 2020; Yu et al. 2020) . The World Health Organization (WHO) declared it a pandemic on 11 March 2020, with total confirmed cases exceeding 121 million cases worldwide and over 2.6 million deaths by 20 th March 2021 . Some people develop severe coronavirus disease 2019 (COVID-19) disease while others remain asymptomatic or have a milder illness course . Identifying predictors of poor outcomes is increasingly gaining importance to help to prioritize resources for high-risk patients and minimize death. Older age and certain comorbid conditions like chronic renal, lung, and heart diseases are established predictors of worse prognosis in COVID-19 patients. In addition, hypoxemia, diarrhea, and high inflammatory markers like C-reactive protein (CRP) and interleukin-6 (IL-6) on admission are also predictors of worse prognosis (Bhargava et al. 2020; Aziz et al. 2020; Shi et al. 2020; Prompetchara, Ketloy, and Palaga 2020).

In these patients, immune cells, namely lymphocytes, have been heavily implicated in controlling disease progression and clinical outcomes. Some studies have demonstrated that higher leukocyte counts, specifically neutrophils Chen et al. 2010; Prompetchara, Ketloy, and Palaga 2020) , and T cell lymphopenia (CD3+, CD8+ Urra et al. 2020 ) and CD4 )) are associated with increased mortality in patients admitted with COVID-19 pneumonia.

Moreover, it was shown that older patients have lower counts and frequency of naïve (CD45RA+CCR7+CD27+CD28+) CD4+T cell contributing to the poor response of T cells (Koch et al. 2008 ). These cells are required for the effective handling of new infections or vaccines (Pawelec 2018; Li, Manwani, and Leng 2011) . It has been already shown that hospitalized COVID-19 patients have reduced (CD45RA+CCR7+CD27+CD28+) CD4+ naïve subsets of T cells compared to healthy uninfected controls (De Biasi et al. 2020) . Furthermore, hospitalized patients with severe manifestations have a lower frequency of exhausted non-cytotoxic T cells (PD-1+ CD57-CD8+) (Kusnadi et al. 2021) .

Monocytes are other immune cells that are also vital for normal and dysregulated immune response.

Monocytopenia was found to be a predictor of worse outcomes in patients with severe community infections and sepsis (Aalto et al. 2007) . Moreover, there is a reduction in the classic monocytes (CD14+CD16-) in severe SARS-CoV-2 infection and an increase in the inflammatory subsets (CD14+CD16+) (Payen et al. 2020) . Monocytes were also recently divided based on size into small and large subsets, coupled with a level of CD14 and CD16 expression into different subsets with different functional abilities (Merah-Mourah et al. 2020 ).

Our study aimed to identify changes in immune variables, namely naïve CD4+ and CD8+, (CD45RA+CCR7+ CD27+CD28+), exhausted T cells CD8+ (PD-1+ CD57-), large and small inflammatory (CD14+CD16+) monocytes, and IL-6 level early in the course of COVID -19 infection as immunological predictors of poor outcomes including ICU admission and death.

This was a prospective observational cohort study conducted from 20 July 2020 to 27 August 2020. A total of 101 COVID-19 cases confirmed by SARS-CoV-2 real-time polymerase chain reaction (RT-PCR) from nasopharyngeal swabs were enrolled (53 non-hospitalized and 48 hospitalized cases).

Inclusion criteria were: patients aged 13 years or older, both genders, confirmed mild SARS-CoV-2 infection in the non-hospitalized group, and confirmed moderate infection in patients hospitalized at the Royal Hospital (RH). Hospitalized patients were recruited within 48 hours of admission. Patients admitted directly to the ICU at the time of enrolment were excluded from the study. Mild cases were those who did not require admission to the hospital due to COVID-19 related illness or oxygen therapy. In contrast, moderate cases were identified as patients with hypoxemia </= 94% requiring oxygen support or those with one or more COVID-19 related organ involvement.

A dedicated clinical team was assigned to collect data and blood samples from the inpatients.

Outpatients were approached through a daily list of confirmed COVID-19 patients provided by the Center of Operation Management for COVID-19 at the Ministry of Health, Oman. Telephonic calls were conducted to get patients' consent to participate in the study after an explanation of the research idea. Patients in the community were visited by two designated researchers the next day. One nominated researcher maintained communication to ensure the adherence of participants. Patients' demographics and clinical characteristics were obtained from non-hospitalized patients directly or for hospitalized ones through electronic hospital records using a unified data collection form. Informed consent was obtained from all enrolled patients. The study was approved by the Central Research Committee at the Ministry of Health in Oman (MoH/CSR/20/23605).

Blood was collected on median days of 6 (2-8) for the hospitalized patients and 7.5 (6.75-8.25) for the non-hospitalized group from the onset of symptoms. Blood was sent for complete blood count (CBC), renal function tests (RFT), liver function tests (LFT), lactate dehydrogenase (LDH), ferritin, D-dimer, coagulation profile, IL-6, and lymphocyte subsets analysis. IL-6 concentration was measured on serum samples using fully automated Elecsys IL-6 immunoassay (electrochemiluminescence immunoassay) on Cobas e 601 immunoassay analyzers (Roche Diagnostics, Switzerland) following the manufacturer's protocol. The IL-6 cut-off used was 7.0 pg/ml. Assessment of different basic lymphocyte and detailed T cell subsets using flow cytometry was performed. DuraClone IM T cell subsets tube (Beckman coulter) that includes CD45RA (clone, 2H4),

CD27(clone, 1A4.CD27), CD4(clone, 13B8.2), CD8(clone, B9.11), CD3(clone, UCHT-1), CD57(clone, NC1), CD45(clone, J33) was used to assess different T cell subsets. DuraClone IM phenotyping basic tube (Beckman coulter) that includes: CD16(3G8), CD56(N901), CD19(J3_119), CD14(RMO52), CD4 (13B8.2), CD8(B9.11), CD3(UCHT-1), CD45(J33) was used for basic lymphocyte staining. Gating strategies are presented in figure1 and 2. A total of 100,000 events were collected.

Briefly, 100 l of blood was added to the tube containing the desired cocktail of antibodies and incubated for 20 minutes at room temperature. 100 l of lysing solution optilyse-B or Versalyse was added according to the manufacture's recommendation. This was followed up with a wash step.

Acquisition of samples was done using Navios flow cytometry (Beckman coulter) and analyzed using Kaluza version 2.1(Beckman coulter).

Results were expressed as medians with their interquartile ranges (IQR) and frequency (%) for continuous and categorical variables, respectively. Assessment of differences between inpatients and outpatients was performed using Chi-squared test, or Fisher's exact test for categorical variables, and Mann-Whitney U test for continuous variables.

In addition, selected variables from the demographic, clinical presentation, inflammatory markers, and all significant immune-subsets were subjected to a univariable logistic regression with the composite outcome of ICU admission and mortality in the first 30 days. Variables significant in the univariable analyses (p <0.05) were assessed using multivariable logistic regression to determine the independent predictors of the mentioned outcome.

An alpha threshold of 0.05 was used for statistical significance. Statistical analysis was performed using R studio (RStudio Team (2016) . RStudio (Version 1.1.456): Integrated Development for R.

Inc., Boston, MA URL).

Results:

During the period between July 2020 and August 2020, a total of 53 mild non-hospitalized and 48 moderate hospitalized patients with SARS-CoV-2 infection were recruited. Demographic, clinical characteristics, and laboratory investigations, including immunological and inflammatory biomarkers, were compared between the two groups.

Hospitalized patients were found to be older ( (Table 3) .

Although there was no difference in the total large CD14+ monocytes, large inflammatory (CD14+ CD16+) monocytes were seen at a higher percentage in the hospitalized group with a median of 27.3% (IQR 12.31-40.62) compared to those non-hospitalized with 15.29 % (IQR 11.39-9.54), p<0.001), (Table 3 , appendix 1).

Higher IL-6 levels in the hospitalized group

In line with previous findings, IL-6 was higher in the hospitalized disease group with a median of 33 pg/mL (IQR 8.36-86.28) compared to the non-hospitalized group 3.71 (IQR 1.58-12.580) (p<0.001), (Table 3 , appendix 1).

Ten out of 48 (21%) hospitalized patients required ICU admission. A total of 7 patients died, five from those who were shifted to the ICU, one of them died while in the ward, and one from the nonhospitalized patients who died before 30 days of illness. Therefore, the total composite endpoint was 12 events (2%).

Factors associated with ICU admission or death

Univariable regression analysis was used to examine potential parameters predictive of ICU admission or death within 30 days, ( 

Earlier studies have shown that in hospitalized patients, inflammatory biomarkers such as CRP, ferritin, LDH, d-dimer, and IL-6 can be used to predict clinical outcomes in COVID-19

patients (Bhargava et al. 2020; Aziz et al. 2020; Shi et al. 2020 ; Prompetchara, Ketloy, and Palaga 2020). The immune system plays a significant role in the disease's clinical manifestation and progression, including the above-mentioned inflammatory markers. Therefore, the focus on immunological predictors that can be used early in the disease course to enable relocation of resources toward those at risk of getting the severe disease should be prioritized. In this study, we have shown that, in addition to elevated level of IL-6, the higher percentage of large inflammatory CD14+ CD16+ monocytes and lower percentage of naive CD27+CD28+ CD4+T cells are independent early immunological prognostic predictors of worse outcome in patients with COVID-19.

Similar to other existing data, in the present study, admitted patients were found to be older, diabetic, and hypertensive compared to those who did not require admission. Moreover, underlying chronic heart, lung and kidney diseases were noted more often in admitted patients than non-admitted patients, which is in agreement with previous studies ( producers (Okada et al. 2008 ). TEM and TEMRA T cells are good cytokine producers, including IL-2, IFN-g, and TNF-a. Moreover, CD27-CD28-T cells have high effector capability similar to the terminal effector T cells TEMRA subset - (Romero et al. 2007; Koch et al. 2008) . Similarly, the combination of PD-1 and CD57 can identify cells with exhausted and or cytotoxic phenotype (Kraaijeveld et al. 2018; Alshekaili et al. 2018 ).

On the other hand, naïve T cell is mainly CD27+CD28+, and it is a good producer of IL-2 that is required for activation and proliferation (Okada et al. 2008; Koch et al. 2008) . CD27+CD28+ naïve T cells are crucial in response to a new virus or vaccine. Those with reduced frequency of naïve T cells, as in the elderly, are at risk of getting a significant disease compared to those with plenty of naïve T cells that can respond better to such new viruses (Cunha et al. 2020 ). This was one of the important explanations for the increased mortality in the elderly after infection with SARS-CoV-2. This is in line with our findings that those with a low percentage of naïve CD4+T cells are at a higher risk of (Khartabil et al. 2020; Lippi and Plebani 2020; Polilli et al. 2020) .

The current study identifies elevated level of IL-6, higher percentage of CD14+CD16+ inflammatory large monocytes and lower percentage of circulating naïve (CD27+CD28+CD45RA+CCR7+) CD4+

T cells early in the disease course as independent early predictors of ICU admission or death in patients with SARS-CoV-2 infection. Such predictors can be used for early identification of patients who might deteriorate and thus need early aggressive interventions. Larger studies are required to validate the current findings aiming toward better early clinical management.

We thank the Ministry of Higher Education, Research and Innovation (MoHERI) for their great contribution in funding this research. We also thank the Tropical and Infectious Diseases Unit at the Royal Liverpool University Hospital for their support and help to facilitate conducting this research and overall supervision of the primary author as part of fellowship training program. We thank dr.

Lamya Al Balushi from Directorate General of Health Services, Ministry of Health, Oman for her help in facilitating fieldwork.

The study was supported by the Ministry of Higher Education, Research and Innovation (MoHERI) in Oman (TRC/CRP/MOH/COVID-19/20/26). 

Monocyte CD14 and soluble CD14 in predicting mortality of patients with severe community acquired infection

STAT3 regulates cytotoxicity of human CD57+ CD4+ T cells in blood and lymphoid follicles', Scientific Reports

Human CD4+ T cells are predominantly distributed among six phenotypically and functionally distinct subsets

Gastrointestinal predictors of severe COVID-19: systematic review and meta-analysis

Inflammatory markers are poorly predictive of clinical outcomes among hospitalized patients with COVID-19', The American journal of emergency medicine

Predictors for Severe COVID-19 Infection

Cellular immune responses to severe acute respiratory syndrome coronavirus (SARS-CoV) infection in senescent BALB/c mice: CD4+ T cells are important in control of SARS-CoV infection

Remodeling of the Immune Response With Aging: Immunosenescence and Its Potential Impact on COVID-19 Immune Response

Marked T cell activation, senescence, exhaustion and skewing towards TH17 in patients with COVID-19 pneumonia

Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study

CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade

A summary of the diagnostic and prognostic value of hemocytometry markers in COVID-19 patients

Multiparameter flow cytometric analysis of CD4 and CD8 T cell subsets in young and old people

Co-inhibitory profile and cytotoxicity of CD57(+) PD-1(-) T cells in end-stage renal disease patients

Severely ill COVID-19 patients display impaired exhaustion features in SARS-CoV-2-reactive CD8<sup>+</sup> T cells

Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths

Frailty, inflammation, and immunity

The critical role of laboratory medicine during coronavirus disease 2019 (COVID-19) and other viral outbreaks

Identification of Novel Human Monocyte Subsets and Evidence for Phenotypic Groups Defined by Interindividual Variations of Expression of Adhesion Molecules

Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells

Phenotypic classification of human CD4+ T cell subsets and their differentiation

Age and immunity: What is "immunosenescence

A Longitudinal Study of Immune Cells in Severe COVID-19 Patients

Comparison of Monocyte Distribution Width (MDW) and Procalcitonin for early recognition of sepsis

Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic

Four Functionally Distinct Populations of Human Effector-Memory CD8<sup>+</sup> T Lymphocytes

Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan

Differential Redistribution of Activated Monocyte and Dendritic Cell Subsets to the Lung Associates with Severity of COVID-19

COVID-19 infection: the perspectives on immune responses

Immune dysfunction following COVID-19, especially in severe patients

Selective CD8 cell reduction by SARS-CoV-2 is associated with a worse prognosis and systemic inflammation in COVID-19 patients

Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention

Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis'

Measures for diagnosing and treating infections by a novel coronavirus responsible for a pneumonia outbreak originating in Wuhan

Gamma-glutamyl transferase (GGT), prothrombin time (PT), or activated partial thromboplastin time (aPTT)